Peripheral and central blood pressure responses of combination aliskiren/hydrochlorothiazide and amlodipine monotherapy in African American patients with stage 2 hypertension: the ATLAAST trial.

The Journal of Clinical Hypertension
Keith C FerdinandRaymond Townsend

Abstract

Efficacy of antihypertensive agents on central blood pressure (BP) in African Americans is not well studied. The authors report on an 8-week double-blind, randomized study of African American patients with stage 2 hypertension that compared brachial and central BP responses (substudy of 53 patients) to combination aliskiren/hydrochlorthiazide (HCTZ) and amlodipine monotherapy. Following a 1- to 4-week washout, initial therapy was aliskiren/HCTZ 150/12.5 mg (n=166) or amlodipine 5 mg (n=166) for 1 week, forced-titrated to aliskiren/HCTZ 300/25 mg or amlodipine 10 mg for 7 weeks. Mean seated systolic BP reductions from baseline was similar with both treatments (-28.6 mm Hg with aliskiren/HCTZ vs -28.2 mm Hg with amlodipine). In the substudy, significantly greater reductions in central systolic BP was observed with aliskiren/HCTZ vs amlodipine (-30.1 mm Hg vs -21.2; P=.031), although 24-hour mean ambulatory BP reductions between the two groups were similar. Central pressure is considered an important risk factor in African Americans, and these findings may suggest a new treatment option for these patients.

References

Jul 14, 1999·Journal of Hypertension·A V FerreiraR S Cunha
Mar 8, 2003·Archives of Internal Medicine·Janice G DouglasUNKNOWN Hypertension in African Americans Working Group of the International Society on Hypertension in Blacks
Jan 31, 2004·American Journal of Hypertension·Trefor MorganAdrianne Anderson
Aug 18, 2004·Journal of Hypertension·Nish ChaturvediChakravarthi Rajkumar
Jan 12, 2005·Journal of Hypertension·William D StrainAngela C Shore
Feb 11, 2005·Journal of the American Society of Nephrology : JASN·Naomi D L Fisher, Norman K Hollenberg
Mar 2, 2005·Obstetrics and Gynecology·Richard K SilverUNKNOWN NICHD EATA TRial Group
Apr 7, 2005·JAMA : the Journal of the American Medical Association·Jackson T WrightUNKNOWN ALLHAT Collaborative Research Group
Jul 16, 2005·Heart·Jawad M Khan, D Gareth Beevers
Jan 18, 2006·The Journal of Clinical Hypertension·Keith C Ferdinand, Elijah Saunders
Jun 15, 2007·Hypertension·Enrico Agabiti-RoseiCharalambos Vlachopoulos
Jan 22, 2008·Journal of the Renin-angiotensin-aldosterone System : JRAAS·Yagiz UresinAndrew Satlin
May 10, 2008·Journal of the American College of Cardiology·Edward P Havranek
Oct 14, 2008·American Journal of Physiology. Heart and Circulatory Physiology·Kevin S HeffernanBo Fernhall
Nov 21, 2008·Expert Review of Cardiovascular Therapy·Keith C Ferdinand, Daphne P Ferdinand
Dec 17, 2008·Circulation·Donald Lloyd-JonesUNKNOWN American Heart Association Statistics Committee and Stroke Statistics Subcommittee
Jan 21, 2010·Journal of Hypertension·Giuseppe Schillaci, Guido Grassi

❮ Previous
Next ❯

Citations

Aug 21, 2015·American Journal of Hypertension·Tracey J McGaugheySachin A Shah
Apr 9, 2014·The Journal of Clinical Hypertension·Ivano BonadeiMarco Metra
Sep 30, 2016·The Journal of Clinical Hypertension·Jessica BarochinerGabriel D Waisman
Jun 10, 2017·Journal of Clinical Medicine·Nikolaos-Dimitrios PantzarisDimitrios Velissaris
Mar 7, 2012·Expert Review of Cardiovascular Therapy·Eric Judd, Edgar A Jaimes
Dec 17, 2019·The Journal of Clinical Hypertension·Hao-Min ChengChen-Huan Chen
Feb 22, 2014·Psychodynamic Psychiatry·Daniel A Plotkin
Apr 21, 2018·Current Cardiology Reports·Adrian OchoaMahboob Rahman

❮ Previous
Next ❯

Related Concepts

Related Feeds

Antihypertensive Agents: Mechanisms of Action

Antihypertensive drugs are used to treat hypertension (high blood pressure) which aims to prevent the complications of high blood pressure, such as stroke and myocardial infarction. Discover the latest research on antihypertensive drugs and their mechanism of action here.